Picture Berlin Partner Hotspot for Startups 650x80px
Organisation › Details

BioNTech (Group)

BioNTech SE is Europe’s largest privately-held biopharmaceutical company pioneering the development of precision immunotherapies for individualized treatment of cancer and prevention of infectious diseases. The company combines all building blocks for more precise and individualized immunotherapies under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based product candidates through innovative chimeric antigen receptors and T-cell receptor-based compounds to novel checkpoint immunomodulators and small molecules. BioNTech’s product development approach has been validated by seven corporate partnerships with, in chronological order, Genmab, Eli Lilly and Company, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and its scientific approach through over 60 peer-reviewed scientific publications. Founded in 2008, BioNTech’s financial shareholders include the Struengmann Family Office as its majority shareholder, Fidelity Management & Research Company, Invus, Janus Henderson Investors, MIG Fonds, Redmile Group, Salvia and several European family offices. *


Period Start 2008-01-01 established
  Predecessor University of Mainz (Johannes Gutenberg University)
Products Industry cancer immunotherapy (immuno-oncology, I-O)
  Industry 2 cancer test
Persons Person Sahin, Ugur (BioNTech 201207 Managing Director BioNTech + Ribological GmbH)
  Person 2 Pötting, Sierk (BioNTech 201409– CFO before Sandoz Inc/Novartis + McKinsey)
Region Region Mainz
  Country Germany
  Street 12 An der Goldgrube
  City 55131 Mainz
  Tel +49-6131-9084-0
    Address record changed: 2020-12-11
Basic data Employees D: 101 to 500 (2014-10-01)
  Currency EUR
  Annual sales 108,589,000 (revenues, consolidated (2019) 2019-12-31)
  Profit -179,172,000 (2019-12-31)
  Cash 451,597,000 (2020-03-31)
    * Document for �About Section�: BioNTech SE. (5/8/19). "Press Release: BioNTech Acquires MabVax Therapeutics’ Antibody Assets to Expand Portfolio". Mainz.
Record changed: 2020-12-30


Picture [iito] Made Without Love 650x80px

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top